Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal anthracycline-based treatment vs conventional care prior to allogeneic stem cell transplantation in higher-risk MDS or oligoblastic AML
2024-515375-35-00Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cytarabine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by GWT-TUD. Primary endpoint: Event-free survival (EFS). Started Oct 2024; status: completed.
02
Drugs
cytarabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-515375-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515375-35-00.